Concomitant methotrexate is often part of the therapeutic regimen for patients receiving aTNF agents, as it can reduce the development of anti-drug antibodies and increase the efficacy of aTNF therapy in the treatment of RA [36-38].
A recent meta-analysis demonstrated that patients with RA treated with aTNF agents had a significant increase in HDL-C in the first 2 to 6 weeks of therapy, after which HDL-C remained stable .
Additionally, results from the Corrona registry demonstrated that patients with RA who received aTNF agents had a reduced risk of CV events compared with patients who received csDMARDs; however, glucocorticoid use, which maybe a surrogate marker of increased inflammation, was associated with a dose-dependent increase in risk of CV events .
This project involves a large number of international collaborators, namely Dr Takahiro Nagayama (Kyoto University, J), Prof Ken Wakamatsu (Gifu University, J), Dr Tom Jarrett (IPAC/Caltech, USA) and Dr Baerbel Koribalski (ATNF, Aus).
Pekeur with Profs Kraan-Korteweg and de Blok, as well as Dr Baerbel Koribalksi (ATNF, AU) completed her study of the HI-to-optical diameter relation based on well-resolved ATCA interferometry data obtained for the first 17 LVHIS (Local Volume HI Survey) galaxies.